Antinociceptive efficacy and plasma concentrations of transdermal buprenorphine in dogs

Pieper, K.; Schuster, T.; Levionnois, O.; Matis, U.; Bergadano, A. (2011). Antinociceptive efficacy and plasma concentrations of transdermal buprenorphine in dogs. Veterinary journal, 187(3), pp. 335-41. Amsterdam: Elsevier 10.1016/j.tvjl.2010.01.013

Full text not available from this repository. (Request a copy)

To assess the antinociceptive efficacy of transdermal (TD) buprenorphine (B) in dogs, a prospective, positive-controlled experimental study was performed in 10 healthy Beagles. In an open label crossover design, the dogs initially received intravenous B (IVB, 0.02 mg kg(-1)) as a positive control, followed by TDB (52.5 mug h(-1)) 4 months later. Blood was collected at regular intervals for determination of the plasma concentrations of B ([B]) and its metabolite norbuprenorphine. The antinociceptive efficacy was assessed using thermal and mechanical models of nociception. The peak concentration [B] was 1.54 ng mL(-1) (+/-1.98) 60 h after TDB application, although three dogs had no measurable [B] after TDB. Maximum thermal threshold (TT) was 52.6 degrees C (+/-0.48) at 1h after IVB administration and 51.63 degrees C (+/-1.01) 72 h after TDB application. The significant increase in TT indicated that effective antinociception was achieved beyond 36 h after the application of TDB, lasting until patch removal. There was hysteresis between [B] and the antinociceptive effect.

Item Type:

Journal Article (Original Article)


05 Veterinary Medicine > Department of Clinical Veterinary Medicine (DKV) > DKV - Anaesthesiology

UniBE Contributor:

Levionnois, Olivier and Bergadano, Alessandra








Factscience Import

Date Deposited:

04 Oct 2013 14:31

Last Modified:

21 Jan 2014 15:05

Publisher DOI:


Web of Science ID:


URI: (FactScience: 218331)

Actions (login required)

Edit item Edit item
Provide Feedback